ZA955784B - Amino purine-beta-D-ribofuranuronamide derivatives - Google Patents

Amino purine-beta-D-ribofuranuronamide derivatives

Info

Publication number
ZA955784B
ZA955784B ZA955784A ZA955784A ZA955784B ZA 955784 B ZA955784 B ZA 955784B ZA 955784 A ZA955784 A ZA 955784A ZA 955784 A ZA955784 A ZA 955784A ZA 955784 B ZA955784 B ZA 955784B
Authority
ZA
South Africa
Prior art keywords
beta
amino purine
ribofuranuronamide
derivatives
ribofuranuronamide derivatives
Prior art date
Application number
ZA955784A
Inventor
Michael Gregson
George Blanch Ewan
Barry Edward Ayres
Suzanne Elaine Keeling
Richard Bell
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ZA955784B publication Critical patent/ZA955784B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA955784A 1994-07-14 1995-07-12 Amino purine-beta-D-ribofuranuronamide derivatives ZA955784B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9414193A GB9414193D0 (en) 1994-07-14 1994-07-14 Compounds

Publications (1)

Publication Number Publication Date
ZA955784B true ZA955784B (en) 1996-08-15

Family

ID=10758311

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA955784A ZA955784B (en) 1994-07-14 1995-07-12 Amino purine-beta-D-ribofuranuronamide derivatives

Country Status (5)

Country Link
AU (1) AU3698295A (en)
GB (1) GB9414193D0 (en)
IL (1) IL114578A0 (en)
WO (1) WO1996002553A2 (en)
ZA (1) ZA955784B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (en) * 1998-01-31 2003-01-31 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AR017457A1 (en) 1998-02-14 2001-09-05 Glaxo Group Ltd COMPOUNDS DERIVED FROM 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY FOR THE TREATMENT OF INFLAMMATORY DISEASES.
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
BR9911482A (en) 1998-06-23 2002-01-22 Glaxo Group Ltd Compound, pharmaceutical composition, use of the compound, and, processes for the treatment or prophylaxis of inflammatory diseases, and for the preparation of a compound
US6376521B1 (en) 1998-07-10 2002-04-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A3 adenosine receptor antagonists
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
ATE336492T1 (en) 2000-01-14 2006-09-15 Us Gov Health & Human Serv METHONOCARBACYCLOALKYLANALOGUES OF NUCLEOSIDES
US20010051612A1 (en) * 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
AU2002362443B2 (en) * 2001-10-01 2008-05-15 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES
CN103087133B (en) 2004-05-26 2016-09-14 伊诺泰克制药公司 Purine derivative is as adenosine A1receptor stimulating agent and usage thereof
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
EP2266994B1 (en) 2004-08-02 2013-04-03 University Of Virginia Patent Foundation 2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
MX2007003271A (en) 2004-09-20 2007-06-05 Inotek Pharmaceuticals Corp Purine derivatives and methods of use thereof.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
EP2532679B1 (en) 2005-10-21 2017-04-12 Novartis AG Human antibodies against il13 and therapeutic uses
CA2627319A1 (en) 2005-11-30 2007-06-07 Prakash Jagtap Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
ATE502943T1 (en) 2006-09-29 2011-04-15 Novartis Ag PYRAZOLOPYRIMIDINES AS PI3K LIPID KINASE INHIBITORS
KR20090075714A (en) 2006-10-30 2009-07-08 노파르티스 아게 Heterocyclic compounds as antiinflammatory agents
WO2009006089A2 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A2 adenosine receptor agonists
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (en) 2009-08-12 2012-02-29 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation.
MY162604A (en) 2009-08-17 2017-06-30 Intellikine Llc Heterocyclic compounds and uses thereof
IN2012DN01453A (en) 2009-08-20 2015-06-05 Novartis Ag
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof
LT2523669T (en) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Combination, kit and method of reducing intraocular pressure
JP2013523739A (en) 2010-03-26 2013-06-17 イノテック ファーマシューティカルズ コーポレイション Method for reducing intraocular pressure in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs thereof
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
WO2012116217A1 (en) 2011-02-25 2012-08-30 Irm Llc Compounds and compositions as trk inhibitors
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
SI2807178T1 (en) 2012-01-26 2017-09-29 Inotek Pharmaceuticals Corporation Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) ) methyl nitrate and processes of preparation thereof
CN104245701A (en) 2012-04-03 2014-12-24 诺华有限公司 Combination products with tyrosine kinase inhibitors and their use
WO2014151147A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
AU2014239222A1 (en) 2013-03-15 2015-10-01 Inotek Pharmaceuticals Corporation Ophthalmic formulations
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
AU2015294889B2 (en) 2014-07-31 2018-03-15 Novartis Ag Combination therapy
CN109879787A (en) * 2019-01-10 2019-06-14 安徽昊帆生物有限公司 Iodo acetylthiocholine, preparation method and its application
TW202140550A (en) 2020-01-29 2021-11-01 瑞士商諾華公司 Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4738954A (en) * 1985-11-06 1988-04-19 Warner-Lambert Company Novel N6 -substituted-5'-oxidized adenosine analogs
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
PT86660B (en) * 1987-02-04 1992-02-28 Ciba Geigy Ag PROCESS FOR THE PREPARATION OF ADENOSIN-5'-CARBOXAMIDE DERIVATIVES

Also Published As

Publication number Publication date
IL114578A0 (en) 1995-11-27
GB9414193D0 (en) 1994-08-31
AU3698295A (en) 1996-02-16
WO1996002553A2 (en) 1996-02-01
WO1996002553A3 (en) 1996-03-07

Similar Documents

Publication Publication Date Title
ZA955784B (en) Amino purine-beta-D-ribofuranuronamide derivatives
ZA952413B (en) 3-aryl-4-hydroxy-delta3-dihydrothiophenone derivatives
NZ297211A (en) Benzylamine derivatives
GB9623908D0 (en) Amino acid derivatives
GB9511077D0 (en) 17B-Substituted-6-azasteroid derivatives
EP0708091A3 (en) Indoloylguanidine derivatives
IL127332A0 (en) Peptide derivatives
ZA953356B (en) Benzocycloalkylazolethione derivatives
EP0692482A3 (en) 1-pyridyltetrazolinone derivatives
GB9702377D0 (en) Peptide derivatives
GB2295614B (en) Novel 5-pyrrolyl-6-halogeno-2-pyridylmethylsulfinylbenzimidazole derivatives
IL112519A0 (en) 5-heteroarylindole derivatives
ZA954125B (en) Novel dialkoxy-pyridinyl-benzimidazole derivatives
GB9624562D0 (en) Peptide derivatives
HU9503582D0 (en) Thienopyridon derivatives
GB9511365D0 (en) Pyridazino-indole derivatives
GB9403729D0 (en) Amine derivatives
GB2291425B (en) 7-Diazo-beta-lactam derivatives
GB2287463B (en) Bis-anthracycline derivatives
GB9421893D0 (en) Benzofuranylimidazoline derivatives
GB9410121D0 (en) Oxodihydroindolylidene derivatives
GB9410868D0 (en) Amino-substituted-3-methyl-benzofurance derivatives
GB9410120D0 (en) Oxodihydroindolylidene derivatives
HU9602147D0 (en) 7-amino-1h-indol derivatives
GB9507400D0 (en) Silyloxy-cyclopropyl-azolyl derivatives